ClinicalTrials.gg
Enrolling by invitationNCT07807995Updated Oct 19, 2026

A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy

A Phase 3 interventional study of Povetacicept in Immunoglobulin A Nephropathy, sponsored by Vertex Pharmaceuticals Incorporated. Enrolling by invitation at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Updated Oct 19, 2026Now Enrolling by invitationFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
605
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies in Glomerulonephritis, IGA with a site in United States — 25 open to participants now, 37 under way, 16 of them phase 3. Glomerulonephritis, IGA · United States.

Planned enrollment
2nd of 67
605 · median 67
Started
2026
with 10 others
Phase 3
21 of 73
8 open now
Primary completion
2029-12
later than 29 of 36 live
Registered
70th of 73
by date

Among the 73 studies in Glomerulonephritis, IGA with a site in United States, this one is the 2nd largest by planned enrollment of the 67 interventional ones that give a count, is one of 11 that started in 2026, is one of 21 in phase 3, reaches primary completion later than 29 of the 36 other live ones, and was the 70th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

25 of the 73 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).

03

Conditions studied

  • Immunoglobulin A Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Completed the Week 104 visit in the parent study VX24-AIS-D08 (NCT06564142) and has not permanently discontinued study drug
  • Estimated (eGFR) greater than or equal to (≥) 15 milliliters per minute (mL/min)/1.73 square meter (m\^2) within 45 days of Day 1 of this study

Key Exclusion Criteria:

- Planned participation in another interventional, therapeutic clinical trial (other than the parent study).

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
605 participants (estimated)

Study arms

  • Experimental
    Povetacicept

    Participants will receive Povetacicept every 4 weeks (Q4W) for 104 weeks.

    Drug: Povetacicept

Interventions

  • Subcutaneous injection administration.

    Also known as: ALPN-303

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Week 112

Secondary outcomes

  1. Percentage Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (uPCR)

    Time frame: From Baseline through Week 104

  2. Total Estimated Glomerular Filtration Rate (eGFR) Slope

    Time frame: From Baseline through Week 104

  3. Change from Baseline in Galactose-deficient immunoglobulin A1 (Gd-IgA1)

    Time frame: From Baseline through Week 104

  4. Percent Change from Baseline in Galactose-deficient immunoglobulin A1 (Gd-IgA1)

    Time frame: From Baseline through Week 104

  5. Proportion of Participants Achieving Clinical Remission

    Clinical remission is defined as UPCR less than (\<)0.5 grams per gram (g/g), absence of hematuria, and eGFR decrease \<25 percentage (%) from baseline.

    Time frame: From Baseline through Week 104

  6. Proportion of Participants to Achieve Hematuria Resolution

    Time frame: From Baseline through Week 104

  7. Time to Kidney Disease Progression

    Kidney disease progression is defined as greater than or equal to (≥) 30% decline in eGFR, end stage kidney disease, or non-accidental death

    Time frame: From Baseline through Week 104

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2029, 39 months after the start.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's planned 39 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Sep 8, 2026
StartActual
Sep 17, 2026
Primary completionEst.
Dec 28, 2029
CompletionEst.
Dec 28, 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 6, 2026
Sites
4 sites added — first site in United States
Show 4 added (4 United States)
  • Western Nephrology - Arvada · Arvada, United States
  • CTR Oakwater, LLC · Orlando, United States
  • Prolato Clinical Research Center - Kirby Dr · Houston, United States
  • Idaho Kidney Institute- Idaho Falls · Idaho Falls, United States
across 2 updates, Oct 6, 2026 – Oct 19, 2026
Start date
Sep 18, 2026→Sep 17, 2026 (actual)
Oct 6, 2026
Contact
No study contact listed any more: removed m•••@vrtx.com · •••6777
Oct 6, 2026
Show all 2 updates
  1. Oct 19, 2026
    1 site added
    Show site
    • Idaho Kidney Institute- Idaho Falls · Idaho Falls, United States
  2. Oct 6, 2026
    Not yet recruiting→Enrolling by invitation
    3 sites added — first site in United States
    Show 3 added (3 United States)
    • Western Nephrology - Arvada · Arvada, United States
    • CTR Oakwater, LLC · Orlando, United States
    • Prolato Clinical Research Center - Kirby Dr · Houston, United States
    Start date Sep 18, 2026→Sep 17, 2026 (now actual)
    Contact No study contact listed any more: removed m•••@vrtx.com · •••6777
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07807995
Responsible party
Sponsor
First posted
Sep 8, 2026
Start date
Sep 17, 2026
Primary completion
Dec 28, 2029 (estimated)
Completion
Dec 28, 2029 (estimated)
Last update
Oct 19, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povetacicept

Start the discussion